TY  - GEN
AU  - Ellis,Peter M
AU  - Leighl,Natasha B
AU  - Hirsh,Vera
AU  - Reaume,M Neil
AU  - Blais,Normand
AU  - Wierzbicki,Rafal
AU  - Sadrolhefazi,Behbood
AU  - Gu,Yu
AU  - Liu,Dan
AU  - Pilz,Korinna
AU  - Chu,Quincy
TI  - A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer
SN  - 1938-0690
PY  - 2016///0815
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Cell Cycle Proteins
KW  - antagonists & inhibitors
KW  - Drug Dosage Calculations
KW  - Drug Interactions
KW  - Drug Resistance, Neoplasm
KW  - Drug Therapy, Combination
KW  - Fatigue
KW  - etiology
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Nausea
KW  - Pemetrexed
KW  - administration & dosage
KW  - Platinum Compounds
KW  - therapeutic use
KW  - Protein Serine-Threonine Kinases
KW  - Proto-Oncogene Proteins
KW  - Pteridines
KW  - Survival Analysis
KW  - Polo-Like Kinase 1
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.cllc.2015.05.010
ER  -